AMD

Leo P. Semes, OD, shared his insights on early detection of age-related macular degeneration during the 17th annual Controversies in Modern Eye Care symposium in Los Angeles, California.

Espansione Group announced the second wave of its major research effort for the prevention and management of dry AMD.

If approved, RVO would be the third indication for Vabysmo in addition to wet age-related macular degeneration and diabetic macular edema.

The treatment is designed to slow the rate of degeneration of retinal cells, slowing the progression of geographic atrophy.

Researchers collaborate to study AMD through database of donor eye tissue to provide new data for study and future treatment targeting.

Alvin Liu, MD, sat down with Sheryl Stevenson, Group Editorial Director, Ophthalmology Times®, to discuss his presentation on deep learning and 3D OCT at the ASCRS annual meeting in San Diego.

Researchers in Australia have identified genes that play a role in oxidative stress and aging in the macula.

David Hutton from Ophthalmology Times and Jay Duker talk about wet AMD and the burdens of treatment on patients thanks to the consistent need for follow-ups and more.

Efavirenz boosts cholesterol turnover in retina, brain.

Ophthalmology Times® talked with Andrew Moshfeghi, MD, MBA, about OTX-TKI in a phase 1 study looking at patients with neovascular AMD this year's ARVO meeting.

Ophthalmology Times® talked with David Tabano, PhD, from Genentech about the company's first real-world data readouts for faricimab in the treatment of DME at this year's ARVO meeting.

Photobiomodulation is an emerging treatment for dry age-related macular degeneration (AMD).

Ophthalmology Times® talked with Allen Chiang, MD, about the assessment of geographic atrophy progression from the Phase 3 OAKS and DERBY trials at this year's ARVO meeting.

Ophthalmology Times® talked with Kaushal Solanki, PhD, CEO and founder of Eyenuk, about EyeArt, an AI system cleared by the FDA to detect diabetic retinopathy at this year's ARVO meeting.

D-4517.2 is a novel precision nanomedicine that inhibits neovascularization by targeting activated microglia and hypertrophic retinal pigment cells, cells responsible for the increased vascularization associated with neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Genentech announced post-hoc data indicating treatment with faricimab-svoa (Vabysmo) led to greater and faster drying of retinal fluid with fewer injections for the treatments of wet AMD and DME, when compared to aflibercept.

Physician discusses clinical presentations, treatment options for 2 cases.

VLTR-557, Valitor's long-acting anti-VEGF biologic in development for durable wet age-related macular degeneration (AMD) treatment, showed that a single intravitreal (ITV) injection has potential to maintain clinical efficacy for more than six months.

Investigators found that Photobiomodulation may be a valid therapeutic option to treat large soft drusen and drusenoid pigment epithelial detachments in dry AMD and may slow the natural disease course.

In a presentation at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans, SB15 demonstrates comparable efficacy, safety, immunogenicity, and pharmacokinetics profiles to reference aflibercept up to Week 56.

Deborah Ferrington, PhD, spoke with on our on-site team at the 2023 ARVO annual meeting in New Orleans about her presentation on using human donor tissue to identify the mechanism responsible for the death of the retinal pigment epithelium (RPE).

Eyevensys reported data showing the efficacy and durability of EYS809, a dual-gene plasmid in development for the treatment of wet age-related macular degeneration (AMD).

At ARVO in New Orleans, Luxa Biotechnology shared an update on the progress of a Phase 1/2a clinical trial evaluating transplantation of RPESC-RPE-4W to treat dry age-related macular degeneration (AMD).

Therapies to target geographic atrophy are in sight.

In a presentation during the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, being held at the Ernest N. Morial Convention Center in New Orleans, Luxa Biotechnology offered details of a clinical trial evaluating transplantation of cells derived from adult retinal pigmented epithelium stem cells to treat dry AMD.